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SUSTAINED RELEASE DRUG DELIVERY
DEVICES
FIELD OF THE INVENTION
The present invention relates to a novel sustained

release drug delivery device comprising an inner core

2

ticularly suitable for treating a patient at a speci?c local
area without having to expose the patient’s entire body
to the drug. This is advantageous because any possible
side effects of the drug could be minimized.
Such systems are particularly suitable for treating
ailments affecting the eye. Advances for administering a
drug to the external surface of the eye are disclosed in
U.S. Pat. No. 4,014,335 to Arnold. Arnold describes

or reservoir containing an agent effective in obtaining a
various ocular inserts that act as a deposit or drug reser
desired local or systemic physiological or pharmacolog
ical effect, a ?rst coating essentially impermeable to the 10 voir for slowly releasing a drug into the tear ?lm for
prolonged periods of time. These inserts are fabricated
passage of the effective agent, and a second coating
of a ?exible polymeric material that is biologically inert,
permeable to the passage of the effective agent. The
non-allergenic, and insoluble in tear ?uid. To initiate the
?rst coating covers at least a portion of the inner core;
therapeutic programs of these devices, the ocular inserts
however, at least a small portion of the inner core is not
are placed in the cul-de-sac between the sclera of the
coated with the ?rst coating layer. The second coating
eyeball and the eyelid for administering the drug to the
layer essentially completely covers the ?rst coating
layer and the uncoated portion of the inner core. The
eye.
portion of the inner core which is not coated with the
Devices formed of polymeric materials that are insol
?rst coating layer allows passage of the agent into the
uble in tear ?uid retain their shape and integrity during

second coating layer thus allowing controlled release.
BACKGROUND OF THE INVENTION

Over the years, various drugs have been developed to

20 the course of the needed therapy to serve as a drug

reservoir for continuously administering a drug to the
eye and the surrounding tissues at a rate that is not

effected by dissolution or erosion of the polymeric ma

assist in the treatment of a wide variety of ailments and
terial. Upon termination of the desired therapeutic pro
diseases. However, in many instances such drugs are 25 gram, the device is removed from the cul-de-sac.
not capable of being administered either orally or intra
Another type of device used for sustained release of a
venously without the risk of various detrimental side
drug to the external surface of the eye, described in U.S.
effects.
Pat. No. 3,416,530, is manufactured with a plurality of

For example, intravenous ganciclovir (GCV) is effec

tive in the treatment of CMV retinitis in AIDS patients,
but bone marrow toxicity limits its usefulness. The inci

dence of neutropenia (absolute neutrophil count
< 1000) during intravenous GCV therapy ranges from
30 to 50%. Continuous maintenance GCV therapy is

capillary openings that communicate between the exte
rior of the device and the interior chamber generally
de?ned from a polymeric membrane. While these capil
lary openings in this construction are effective for re

leasing certain drugs to the eye, they add considerable
complexity to the manufacture of the device because it
35
necessary to prevent progression or recrudescence of
is dif?cult to control the size of these openings in large
the disease, but despite maintenance therapy 30 to 50%
scale manufacturing using various polymers.
of patients experience a relapse during treatment. Other
Another device, described in U.S. Pat. No. 3,618,604,
problems associated with systemic GCV administration
does
not involve such capillary openings, but instead
include the risk of sepsis related to permanent indwell
ing catheters and the inability to receive concurrent 40 provides for the release of the drug by diffusion through
a polymeric membrane. The device, in a preferred em
therapy with zidovudine (AZT) which has been shown
bodiment, as disclosed in that patent, comprises a sealed
to prolong life and improve the immune function in

container having the drug in an interior chamber. None
theless, as described in U.S. Pat. No. 4,014,335, certain
Intravitreal GCV injections of 200 to 400 pg adminis
tered once or twice weekly have resulted in temporary 45 problems have been identi?ed with such devices such as
the dif?cult task of sealing the margins of the membrane
remission of CMV retinitis in AIDS patients. Intravit
to form the container. In addition, stresses and strains
real GCV injections may provide a higher intraocular
introduced into the membrane walls from deformation
drug concentration than systemic therapy and reduce
during manufacturing of those devices may cause the
the incidence of neutropenia. Current treatment of
reservoir to rupture and leak.
CMV retinitis in AIDS patients is clearly suboptimal.
Another such device, described in U.S. Pat. No.
Ganciclovir is virustatic and thus disease inhibition

AIDS patients.

requires maintenance drug administration.
Due to the risks that certain drugs impose, research
ers have developed systems for administering such

4,014,335, comprises a three-layered laminant having a
pair of separate and discrete ?rst and third walls formed
of a material insoluble in tear ?uid with one of the walls

drugs to aid in the treatment of these ailments and dis 55 formed of a drug release material permeable to the
passage of drug and the other wall formed of a material
eases. Many of these systems provide a release rate
impermeable to the passage of the drug.
which reduces the occurrence of detrimental side ef
The above described systems and devices are in
fects.
tended to provide sustained release of drugs effective in
One such delivery device is an orally administered
treating patients at a desired local or systemic level for
pill or capsule which contains a drug encapsulated
obtaining certain physiological or pharmacological ef
within various layers of a composition that dissolves
over a period of time in the digestive tract, thereby ' fects. However, there are many disadvantages associ
ated with their use including the fact that it is often
allowing a gradual or slow release of the drug into the
times dif?cult to obtain the desired release rate of the
system.
Another type of device for controlling the adminis 65 drug. The need for a better release system is especially
signi?cant in the treatment of CMV retinitis. Thus,
tration of such drugs is produced by coating a drug with
there remains a long-felt need in the art for an improved
a polymeric material permeable to the passage of the
system for providing sustained release of a drug to a
drug to obtain the desired effect. Such devices are par

3
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FIG. 4 is a graph showing the concentration of ganci
clovir found in humans and delivered by an ocular
device of the present invention over time;
FIG. 5 is a graph showing the concentration of 5

patient to obtain a desired local or systemic physiolog
ical or pharmacological effect. In addition, all of these
devices release their drug into the tear ?lm. If relatively
high levels are required inside the eye, such devices are

essentially useless.

fluorouracil (S-FU) delivered by devices of the present
invention over time; and
FIG. 6 illustrates the intraocular pressure of monkeys
over time, wherein under the conjunctiva of one eye of
each monkey was implanted a device of the present
invention.

SUMMARY OF THE INVENTION

It is, therefore, a primary objective of the present
invention to provide a device suitable for the controlled
and sustained release of a composition effective in ob
taining a desired local or systemic physiological or

DETAILED DESCRIPTION OF THE
PREFERRED EMBODIMENTS OF THE
INVENTION

pharmacological effect.
The device, in one embodiment, includes an inner
core or reservoir which contains an agent effective in

obtaining the desired effect. The device further includes 15

a ?rst coating layer. The ?rst coating layer is essentially

More speci?cally, the present inventors have surpris

portion of the inner core. The ?rst coating layer blocks

ingly discovered a device that is suitable for the con
trolled and sustained release of an agent effective in
obtaining a desired local or systemic physiological or

passage of the agent from the inner core at those sides

pharmacological effect.

where it contacts the inner core. The remaining portion 20
of the inner core which is not blocked allows a con
trolled amount of the agent from the inner core to pass

The device includes an inner core or reservoir which
contains an agent effective in obtaining a desired effect.
The device further includes a ?rst coating layer and a

into the second coating layer. The second coating layer

second coating layer. The ?rst coating layer covers

impermeable to the passage of the agent and covers a

is permeable to the passage of the agent and covers

essentially the entire ?rst coating layer and the exposed
inner core. The ?rst coating layer is positioned between

25

the inner core and the second coating layer in order to
control the rate at which the agent permeates through

the second coating layer-.
Another object of the present invention is to provide
a method for treating a mammalian organism, e. g., hu
man, to obtain a desired local or systemic physiological

or pharmacological effect. The method includes posi
tioning the sustained released drug delivery system at an

30

only a portion of the inner core and is impermeable to
the passage of the agent. The second coating layer cov
ers all of the inner core and the ?rst coating layer and is
permeable to the passage of the agent. The portion of
the inner core that is not coated with the ?rst coating
layer facilitates passage of the agent through the second

coating layer.
Speci?cally, the ?rst coating layer is positioned be
tween the inner core and the second coating layer such
that it blocks the passage of the agent through the adja

cent portions of the second coating layer thus control

area wherein release of the agent is desired and allowing 35 ling the rate of passage of the agent.
the agent to pass through the second coating to the
FIG. 1 illustrates one embodiment of the sustained
desired area of treatment.

release drug delivery device of the present invention.

Another object of the present invention is to provide
an ocular device suitable for direct implantation into the

While the device shown in FIG. 1 is cylindrical, the
device could be any shape. The device comprises an
inner core or reservoir 5, an impermeable coating 10
which is impermeable to the passage of the agent in the

vitreous of the eye. Such devices of the present inven
tion are surprisingly found to provide sustained con
trolled release of various compositions to treat the eye
without risk of detrimental side effects.

core or reservoir 5, and a permeable coating 15 which is
permeable to the passage of the agent in the core or
Another object of the present invention is to provide
reservoir 5. FIG. 1 further shows an impermeable cap
an ocular delivery system that could be applied to an 45 20 and suture tag 25.
intraocular lens to prevent inflamation or posterior
FIG. 2 illustrates, in cross section, the device shown
capsular opaci?cation.
in FIG. 1. As illustrated, there may be a permeable
With the foregoing as well as other objects, advan
coating 30 between the core or reservoir 5 and the

tages, features and aspects of the invention that will
impermeable coating 10. The permeable coating 30 may
become hereinafter apparent, the nature of the inven 50 be made of the same material as the permeable coating
tion may be more clearly understood by reference to the
15. In the embodiment illustrated in FIG. 2, the imper
detailed description of the invention and to the ap
meable cap 20 is positioned such that there is a passage

pended claims.
BRIEF DESCRIPTION OF THE DRAWINGS
In the drawings, which are not drawn to scale, but are
set forth to illustrate various embodiments of the inven
tion, the ?gures are as follows:
FIG. 1 is an enlarged view of one embodiment of the

sustained release drug delivery device showing inner
core, ?rst coating layer and second coating layer;

35 which allows passage of the agent in the core or

reservoir. The impermeable coating 20 is positioned
55 between the permeable coating 15 and the reservoir or

core 5. The suture tag 25 is attached to the permeable

coating 15.
The invention further relates to a method for treating
a mammalian organism to obtain a desired local or sys

temic physiological or pharmacological effect. The
method includes administering the sustained release
FIG. 2 is an enlarged cross sectional schematic of one
drug delivery system to the mammalian organism and
embodiment of the sustained release drug delivery de
allowing the agent effective in obtaining the desired
vice showing inner core, ?rst coating layer and second
local or systemic effect to pass through the second
65 coating to contact the mammalian organism. The term
coating layer;
FIG. 3 is a graph showing the concentration of ganci
administering, as used herein, means positioning, insert
clovir found in test rabbits and delivered by an ocular
ing, injecting, implanting, or any other means for expos
ing the device to a mammalian organism. The route of
device of the present invention over time;

5
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such as nitrofurazone and sodium propionate; antialler
administration depends on a variety of factors including
genics such as antazoline, methapyriline, chlorphenira
type of response or treatment, type of agent and pre
mine, pyrilamine and prophenpyridamine; anti-in?am
ferred site of administration.
matories such as hydrocortisone, hydrocortisone ace
The devices in certain embodiments have applicabil
ity in providing a controlled and sustained release of 5 tate, dexamethasone 21-phosphate, fluocinolone, med
rysone, methylprednisolone, prednisolone 2l-phos
agents effective in obtaining a desired local or systemic

physiological or pharmacological effect relating at least

phate, prednisolone acetate, ?uoromethalone, betame

to the following areas: treatment of cancerous primary

thasone and triminolone; decongestants such as phenyl
ephrine, naphazoline, and tetrahydrazoline; miotics and

tumors, (e.g., glioblastoma); chronic pain; arthritis;

rheumatic conditions; hormonal de?ciencies such as 10 anti-cholinesterase such as pilocarpine, eserine salicyl

diabetes and dwar?sm; and modi?cation of the immune

ate, carbachol, di-isopropyl ?uorophosphate, phospho

response such as in the prevention of transplant rejec
tion and in cancer therapy. A wide variety of other

line iodine, and demecarium bromide; mydriatics such
as afropine sulfate, cyclopentolate, homatropine, sco

disease states may also be prevented or treated using the

polamine, tropicamide, eucatropine, and hydroxyam

drug delivery device of the present invention. Such

phetamine; and sympathomimetics such as epinephrine.

disease states are known by those of ordinary skill in the
art. For those not skilled in the art, reference may be

Once again, reference may be made to any standard

pharmaceutical textbook such as Remington’s Pharma
ceutical Sciences for the identify of other agents.
Any pharmaceutically acceptable form of such a
compound may be employed in the practice of the pres

made to Goodman and Gilman, The Pharmacological

Basis of Therapeutics, 8th Ed., Pergamon Press, NY,
1990; and Remington's Pharmaceutical Sciences, 18th

ent invention, i.e., the free base or a pharmaceutically
acceptable salt or ester thereof. Pharmaceutically ac

Ed., Mack Publishing Co., Easton, Pa., 1990; both of
which are incorporated by reference herein.
In addition, the devices are suitable for use in treating

ceptable salts, for instance, include sulfate, lactate, ace
tate, stearate, hydrochloride, tartrate, maleate and the
mammalian organisms infected with AIDS and AIDS
related opportunistic infections such as cytomegalovi 25 like.
A large number of polymers can be used to construct
rus infections, toxoplasmosis, pneumocystis carinii and
the devices of the present invention. The only require
mycobacten'um avium intercellular.
ments are that they are inert, non-immunogenic and of

The devices are particularly suitable for treating ocu

lar conditions such as glaucoma, proliferative vi

treoretinopathy, diabetic retinopathy, uveitis, and kera

30

titis. The devices are also particularly suitable for use as

an ocular device in treating mammalian organisms suf
fering from cytomegalovirus retinitis wherein the de
vice is surgically implanted within the vitreous of the

the desired permeability.
Materials that may be suitable for fabricating the ?rst
or second coating layer of the device include naturally
occurring or synthetic materials that are biologically
compatible with body ?uids and eye tissues, and essen

tially insoluble in body ?uids with which the material

35 will come in contact. The use of rapidly dissolving
eye.
materials or materials highly soluble in eye ?uids are to
As described above, the inner core or reservoir con
be avoided since dissolution of the wall would affect the
tains an agent effective in obtaining a desired local or

constancy of the drug release, as well as the capability
systemic physiological or pharmacological effect. The
of the system to remain in place for a prolonged period
following classes of agents could be incorporated into
the devices of the present invention: anesthetics and 40 of time.
Naturally occurring or synthetic materials that are
pain killing agents such as lidocaine and related com

biologically compatible with body ?uids and eye tissues

pounds and benzodiazepam and related compounds;
‘ anti-cancer agents such as S-fluorouracil, adriamycin

and essentially insoluble in body ?uids which the mate

and related compounds; anti-in?ammatory agents such

rial will come in contact include, but are not limited to,

as 6-mannose phosphate; anti-fungal agents such as 45 polyvinyl acetate, cross-linked polyvinyl alcohol, cross

linked polyvinyl butyrate, ethylene ethylacrylate co

?uconazole and related compounds; anti-viral agents
such as trisodium phosphomonoformate, tri?uoro

polymer, polyethyl hexylacrylate, polyvinyl chloride,
polyvinyl acetals, plasiticized ethylene vinylacetate
copolymer, polyvinyl alcohol, polyvinyl acetate, ethyl

thymidine, acyclovir, ganciclovir, DDI and AZT; cell
transport/mobility impending agents such as colchi

cine, vincristine, cytochalasin B and related com 50 ene vinylchloride copolymer, polyvinyl esters, polyvi

nylbutyrate, polyvinylformal, polyamides, polymethyl
methacrylate, polybutylmethacrylate, plasticized poly
vinyl chloride, plasticized nylon, plasticized soft nylon,

pounds; antiglaucoma drugs such as beta-blockers:

timolol, betaxolol atenolol, etc; immunological response
modifiers such as muramyl dipeptide and related com

plasticized polyethylene terephthalate, natural rubber,

pounds; peptides and proteins such as cyclosporin, insu

polyisoprene, polyisobutylene, polybutadiene, polyeth

lin, growth hormones, insulin related growth factor,

ylene, polytetrafluoroethylene, polyvinylidene chlo
ride, polyacrylonitrile, cross-linked polyvinylpyrroli
done, polytri?uorochloroethylene, chlorinated poly
ethylene, poly(l,4°-isopropylidene diphenylene carbon
ate), vinylidene chloride, acrylonitrile copolymer, vinyl
chloride-diethyl fumerale copolymer, silicone rubbers,
especially the medical grade polydimethylsiloxanes,
ethylene-propylene rubber, silicone-carbonate copoly

heat shock proteins and related compounds; steroidal
compounds such as dexamethasone, prednisolone and
related compounds; and carbonic anhydrize inhibitors.
In addition to the above agents, other agents are
suitable for administration to the eye and its surround
ing tissues to produce a local or a systemic physiologic

or pharmacologic bene?cial effect. Examples of such
agents include antibiotics such as tetracycline, chlortet

racycline, bacitracin, neomycin, polymyxin, gramicidin,
goxytetracycline, chloramphenicol, gentamycin, and

mers, vinylidene chloride-vinyl chloride copolymer,

erythromycin; antibacterial such as sulfonamides, sulfa

vinyl chloride-acrylonitrile copolymer and vinylidene
chloride-acrylonitride copolymer.

cetamide, sulfamethizole and sul?soxazolc; antivirals,
including idoxuridine; and other antibacterial agents

ent invention may be made of any of the above-listed

65

Speci?cally, the ?rst layer of the device of the pres
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polymers or any other polymer which is biologically
compatible with body ?uids and eye tissues, essentially

stant, a steady state ?ux of the effective agent will be
established in accordance with Fick’s Law of Diffusion.

insoluble in body ?uids which the material will come in
contact and essentially impermeable to the passage of
the effective agent. The term impermeable, as used
herein, means that the layer will not allow passage of
the effective agent at a rate required to obtain the de
sired local or systemic physiological or pharmacologi
cal effect.
The ?rst layer must be selected to be impermeable, as
described above, to the passage of the agent from the
inner core out to adjacent portions of the second coat

The rate of passage of the drug through the material by
diffusion is generally dependent on the solubility of the
drug therein, as well as on the thickness of the wall.

This means that selection of appropriate materials for
fabricating the wall will be dependent on the particular
drug to be used.
The rate of diffusion of the effective agent through a

polymeric layer of the present invention may be deter
mined via diffusion cell studies carried out under sink
conditions. In diffusion cell studies carried out under

ing layer. The purpose is to block the passage of the
sink conditions, the concentration of drug in the recep
agent to those portions and thus control the release of
tor compartment is essentially zero when compared to
the agent out of the drug delivery device.
15 the high concentration in the donor compartment.
The composition of the ?rst layer, e. g., the polymer,
Under these conditions, the rate of drug release is given
must be selected so as to allow the above-described

controlled release. The preferred composition of the

by:

?rst layer will vary depending on such factors as the
active agent, the desired rate of control and the mode of

administration. The identity of the active agent is im
portant since the size of the molecule, for instance, is
critical in determining the rate of release of the agent
into the second layer.

where Q is the amount of drug released, t is time, D is
the diffusion coef?cient, K is the partition coef?cient, A

is the surface area, DC is the difference in concentration
of the drug across the membrane, and h is the thickness
Since the ?rst coating layer is essentially imperme 25 of the membrane.
able to the passage of the effective agent, only a portion
In the case where the agent diffuses through the layer
of the inner core or reservoir may be coated with the
via water ?lled pores, there is no partitioning phenom
?rst coating layer. Depending on the desired delivery
ena. Thus, K can be eliminated from the equation.
rate of the device the ?rst coating layer may coat only
Under sink conditions, if release from the donor side is
a small portion of the surface area of the inner core for
very slow, the value DC is essentially constant and
faster release rates of the effective agent or may coat
equal to the concentration of the donor compartment.
large portions of the surface area of the inner core for
Release rate therefore becomes dependent on the sur
slower release rates of the effective agent.
face area (A), thickness (h) and diffusivity (D) of the
For faster release rates, the ?rst coating layer may
membrane. In the construction of the device of the
coat up to 10% of the surface area of the inner core. 35

Preferably, approximately 5-10% of the surface area of
the inner core is coated with the ?rst coating layer for
faster release rates.

For slower release rates, the ?rst coating layer may

present invention, the size (and therefore, surface area)
is mainly dependent on the size of the effective agent.
Thus, permeability values may be obtained from the
slopes of a Q versus time plot. The permeability P, can
be related to the diffusion coef?cient D, by:

coat at least 10% of the surface area of the inner core.
Preferably, at least 25% of the surface area of the inner

core is coated with the ?rst coating layer. For even
slower release rates, at least 50% of the surface area

Once the permeability is established for the coating

may be coated. For. even slower release rates, at least
permeable to the passage of the agent, the surface area
75% of the surface area may be coated. For even slower 45 of the agent that must be coated with the coating imper
release rates, at least 95% of the surface area may be
meable to the passage of the agent may be determined.
coated.
This is done by progressively reducing the available
Thus, any portion of the surface area of the inner core
surface area until the desired release rate is obtained.

up to but not including 100% may be coated with the
?rst coating layer as long as the desired rate of release
of the agent is obtained.
The ?rst coating may be positioned anywhere on the
inner core, including but not limited to the top, bottom
or any side of the inner core. In addition, it could be on
the top and a side, or the bottom and a side, or the top 55
and the bottom, or on opposite sides or on any combina

tion of the top, bottom or sides.

The second layer of the device of the present inven
tion must be biologically compatible with body ?uids
and eye tissues, essentially insoluble in body ?uids
which the material will come in contact and permeable
to the passage of the agent or composition effective in

obtaining the desired effect.

Exemplary microporous materials suitable for use as
a second coating layer, for instance, are described in

U.S. Pat. No. 4,014,335 which is incorporated herein by
reference in its entirety. These materials include cross

linked polyvinyl alcohol, polyolefms or polyvinyl chlo
rides or cross-linked gelatins; regenerated, insoluble,
nonerodible cellulose, acylated cellulose, esteri?ed cel
luloses, cellulose acetate propionate, cellulose acetate
butyrate, cellulose acetate phthalate, cellulose acetate

diethyl-aminoacetate; polyurethanes, polycarbonates,
and microporous polymers formed by co-precipitation
of a polycation and a polyanion modi?ed insoluble col

lagen. Cross-linked polyvinyl alcohol is preferred. The
second coating layer is selected so as to slow release of
the agent from the inner core into contact with a mam

The effective agent diffuses in the direction of lower
malian organism, e.g., a human. The second coating
chemical potential, i.e., toward the exterior surface of 65 layer need not provide gradual release or control of the
the device. At the exterior surface of the device, equilib
agent into the biological environment, however, the
rium is again established. When the conditions on both
second coating layer may be advantageously selected to
sides of the second coating layer are maintained con

also have that property or feature.

5,378,475
The devices of the present invention may be made in
a wide variety of ways, such as by obtaining an effective
amount of the agent and compressing the agent to a

desired shape. Once shaped, a first coating layer may be
applied. In the case of the ethylene vinyl acetate, the
?rst coating layer may be applied directly in the form of
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systemic levels and avoid premature metabolism. In
addition, such devices may be administered orally.
In one embodiment of the invention, an ocular device
containing ganciclovir as the effective agent in an effec
tive amount to prevent a virus from replicating may be

a sheet or membrane to the outer surface of the agent.

prepared. As further shown in the Examples which
follow, such devices may be used to effectively combat

Optionally, the effective agent may have a permeable
coating applied to its entire surface prior to coating

when surgically implanted into the vitreous of the eye.

and inhibit reproduction of cytomegalovirus retinitis,

with the ?rst coating layer. See FIG. 2. Once the ?rst 10 Such devices may remain in the vitreous permanently
after treatment is complete. The preferred amount of
ganciclovir used in these devices ranges from about 0.01
mg to about 20 mg. More preferably, such devices con
hol, the second coating may be applied by dipping the
tain from @out 2 mg to about 10 mg of ganciclovir.
device one or more times in a solution containing the
These preferred ranges may provide sustained release of
desired polymer. Optionally, the second coating layer
the ganciclovir for a period of from several hours to
may be applied by dropping, spraying, brushing or
over one year. The preferred ?rst coating layer is ethyl
other means of coating the outer surface of the device

coating layer is applied to the device, the second coat
ing layer may be applied. In the case of polyvinyl alco

with the polymer solution. When using a polyvinyl
alcohol solution to obtain the second coating layer, the
desired thickness may be obtained by applying several
coats. Each coat may be dried prior to applying the next
coat. Finally, the device may be heated to adjust the

ene vinyl acetate. The preferred second coating layer is
polyvinylalcohol. When such devices are prepared for
20 implantation within the vitreous of the eye, it is pre

ferred that the device does not exceed about 5 millime

ters in any direction. Thus, the cylindrical device
shown in FIG. 2 would preferably not exceed 5 millime
ters in height or diameter. In addition, the preferred
The above description of how to make the devices of
the present invention is merely illustrative and should 25 thickness'of the ?rst coating layer ranges from about 0.1
to about 1.0 millimeters. The preferred thickness of the
not be considered as limiting the scope of the invention
second coating layer ranges from about 0.1 to about 2.0
in any way, as various compositions are well known by
millimeters.
those skilled in the art. In particular, the methods of
In another embodiment of the invention, an ocular
making the device depends on the identity of the active
agent and polymers selected. Given the active agent, 30 device containing S-FU as the effective agent may be
prepared. As further shown in the Examples which
and the composition of both the ?rst coating and the
follow, such devices may be used to effectively main
second coating, one skilled in the art could easily make
tain the'intraocular pressure of glaucoma patients after
the devices of the present invention using conventional

permeability of the outer coating.

coating techniques.

?lter surgery when implanted under the conjunctiva of

The method for treating a mammalian organism to 35 the eye. The preferred amount of ganciclovir used in
these devices ranges from about 0.01 mg to about 20
obtain a desired local or systemic physiological or phar
mg. More preferably, such devices contain from about 2
macological effect includes administering the sustained
mg to about 15 mg. These preferred ranges may provide
release drug delivery device of the present invention to
sustained release of the S-FU for a period of from sev
the mammalian organism and allowing the agent to pass
through the device to come in direct contact with the 40 eral hours to over 2 months. Preferred materials include

mammalian organism.
The drug delivery system of the present invention
may be administered to a mammalian organism via any
route of administration known in the art. Such routes of

ethylene vinyl acetate as the ?rst coating layer and
polyvinyl alcohol as the second coating layer. The pre
ferred thickness of the ?rst coating layer ranges from
about 0.01 to about 1.0 millimeters. The preferred thick

administration include intraocular, oral, subcutaneous,

45 ness of the second coating layer ranges from about 0.01

intramuscular, intraperitoneal, intranasal, dermal, and

to about 2.0 millimeters.
Optionally, one or more of the devices could be at
tached to an intraocular lens or the haptic extending

the like. In addition, one or more of the devices may be
administered at one time or more than one agent may be
included in the inner core.

The drug delivery system of the present invention is
particularly suitable for direct implantation into the
vitreous of the eye and for application to an intraocular
lens.

therefrom. Intraocular lenses having the devices of the
present invention attached thereto and containing
5-FU, colchicine or dexamethasone are particularly

suitable for treating patients that have undergone extra
capsular cataract surgery. Speci?cally, such devices

may be used to reduce proliferation of remnant lens
These methods of administration and technique for
their preparation are well known by those of ordinary 55 cells thus preventing or reducing posterior capsular

skill in the art. Techniques for their preparation are set

opaci?cation.

forth in Remingtan’s Pharmaceutical Sciences.
The drug delivery system may be administered for a
sufficient period of time and under conditions to allow

While the above described embodiments of the inven
tion are described in terms of preferred ranges of the

treatment of the disease state of concern. I

the preferred ?rst and second coating, these preferences

For localized drug delivery, the devices may be sur
gically implanted at or near the site of action. This is the
case for devices of the present invention used in treating
ocular conditions, primary tumors, rheumatic and ar

be readily understood by one skilled in the art, the pre
ferred amounts, materials and dimensions depend on the

This is the case when devices are to give sustained

such as the disease state being treated, the age and con

amount of effective agent, and preferred thicknesses of
are by no means meant to limit the invention. As would

method of administration, the effective agent used, the
65 polymers used, the desired release rate and the like.
thritic conditions, and chronic pain.
Likewise, actual release rates and release duration de
For systemic relief, the devices may be implanted
pend on a variety of factors in addition to the above
subcutaneously, intramuscularly or intraperitoneally.
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dition of the patient, the route of administration as well
as other factors which would be readily apparent to
those skilled in the art.

In Vivo Testing of Devices
Devices were surgically implanted into both the sub
conjunctival space and the vitreous of albino rabbits.

The following examples are merely illustrative of the
present invention and they should not be considered as
limiting the scope of the invention in any way, as these

After 10 days, the animals were sacri?ced and a histo

logical examination was performed. In another group of
animals, devices were implanted into the posterior

examples and other equivalents thereof will become
more apparent to those skilled in the art in light of the

present disclosure.
EXAMPLE 1
Intraocular Sustained Release of Antiviral Agents
This example demonstrates that the severe problems
associated with present GCV therapy may be avoidable

12

chamber of the eye and samples of vitreous humour was
periodically removed. In a third group of animals de
10 vices were implanted into the vitreous of both eyes. The

animals were killed 10, 30, 40, 70 and 80 days after
implantation of the devices. The devices and vitreous
samples removed for analysis. The concentration of
GCV in these samples was determined by HPLC with

by delivering the drug locally thus avoiding high sys
temic drug levels. The present inventors have devel
oped an implantable device that will release GCV
within the eye for over 90 days. The device is composed
of 6 mg GCV encased in layers of ethylene vinyl acetate 20

(EVA) and polyvinyl alcohol (PVA).
Characteristics of Polymers

EVA membranes were prepared by compressing

UV detection at 254 nm. A C-l8 reverse phase column
was used with mobile phase of 0.02% ammonium ace

tate buffer (pH 4.0) and a ?ow rate of 1 ml/min. The
effect of implantation on retinal function was assessed

by performing electroretinogram (ERG) examinations
before and after the study.
Histologic examination gave no indication of toxicity
or inflammatory reaction due to the implantation of the
device. Some in?ammation was noted around the suture

EVA at 180° C. under 5 tons of pressure. PVC mem

branes were prepared from solutions of PVA which 25 used to hold the device in place suggesting that this
produced a worse reaction than the device itself. Analy
were dried to a ?lm and then heated to 125, 150 or 180°
sis of vitreal samples showed that the device maintained
C. The permeability of EVA and PVA membranes to
GCV
levels in the vitreous at or above 2 rig/ml for over
GCV was measured in vitro using parallel glass diffu
80 days. The ERG data suggests that the levels of GCV
sion chambers (Crown Glass Co., Somerville, NJ).
One ml solutions of GCV were prepared in normal 30 obtained cause no retinal toxicity in the rabbit eye. The

possibility exists for drug resistance to develop in CMV

phosphate buffer (pH 7.4) and applied to the donor side

of the chambers. The permeation of GCV across the
membranes to the receptor compartment was measured
for 3 hours at 37° C. The devices were found to release

GCV in a linear manner for approximately 120 days in 35
vitro with a mean release rate of approximately 50

although there have been no reports of this as yet. Resis
tance to GCV, should it occur, could be countered by
the use of other drugs (Foscarnet or tri?uorothymidine)
in similar release devices.

CONCLUSION

lbs/day

The implantation of controlled release devices for the

Preparation and Testing of the Devices

release of GCV appears to offer some signi?cant advan
6 mg pellets of GCV were prepared by direct com 40 tages over existing therapy. The work performed in
rabbits indicates that vitreal concentrations of GCV can
pression using a 2.5 mm die. These were surrounded on
be maintained above the ID 100 for CMV for a pro
three sides with the impermeable EVA membrane and
longed period without high systemic exposure. This
then coated in a 10% PVA solution. After being al
will, if effective, treat potentially blinding CMV retini
lowed to dry for 24 hours, the device was cured at 180°
C. for 4.7 hours to further reduce the release rate. The 45 tis and allow concurrent therapy of AZT for HIV. It is
anticipated that fewer complications will arise from this
release rate of GCV from the devices prepared above
procedure than occur in repeated intravitreal injections.
was measured in vitro by immersing each device in 5 ml

of isotonic phosphate buffer (pH 7.4). One ml samples
were periodically withdrawn and replaced with fresh
buffer and the buffer solution was changed every 10 50
days to avoid microbial growth.
The apparent permeability coefficient of GCV across
PVA membranes was dependent on the temperature

which they had been treated. The change in physical
properties of the membranes is due to alterations in 55

crystal structure of polymer. The permeability of GCV

across EVA membranes was too low for permeability

across PVA membranes is set forth in Table l‘below.

11.2). The precipitated product was then puri?ed with

PERMEABILITY OF GCV ACROSS PVA MEMBRANE
TREATED AT VARIOUS TEMPERATURES

Papp (cm/s X l0-7)
+/-— SD, N = 4

125
150

8-3 +/— 0.6
2.1 +/— 0.2

180

0.9 +/— 0.1

Ganciclovir was obtained from Syntex Laboratories
as a free acid in powdered form. Alternatively, the free

two successive recrystallizations from 95% ethanol.
The buffer solution was composed of sodium bicarbon
ate (0.68%), potassium bicarbonate (0.03%), and so
dium chloride (0.65%), in distilled water. The pH of the

TABLE 1
Membrane

Intravitreal Sustained Release of Ganciclovir:
Membrane Permeability and Device Construction
The following paragraphs illustrate the membrane
permeability and device construction of particular em
bodiments of the present invention.

acid of ganciclovir was prepared by neutralizing an
aqueous solution of the commercially available salt (pH

coefficients to be calculated. The permeability of GCV

Treatment ('‘C.)

EXAMPLE 2

buffer solution was adjusted to 7.4 prior to use. Polyvi
65

nyl alcohol (PVA) of 76—78,000 M.W. and 98% hydra
tion was obtained from Aldrich Chemical Co. Ethylene
vinyl acetate was obtained from Du Pont of Wilming

ton (trade name ELVAX, grade 40w).

13
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Release Rate Studies

Diffusion Cell Studies

The devices were placed in 10 m1 of isotonic buffered
saline at 37° C. This solution was periodically sampled
and changed to maintain sink conditions. The concen
tration of GCV in these samples was determined by

PVA membranes were prepared by dissolving 4
grams of PVA in 200 ml of distilled water at 60° C. The
PVA solution was allowed to cool to 22° C. and the
entire mixture was poured so that it completely covered
a silicanized glass slab measuring 35 cm by 46 cm. After
drying for 16 hours, the PVA ?lm was removed from
the slab. Membranes prepared in this fashion were then

HPLC with UV detection at 254 nm absorbance. Ab

Diffusion cell studies were performed by placing the
membranes between the compartments of a glass diffu

sorbance values of the samples were converted to drug
concentrations and cumulative drug release (average of
three trials) was plotted against time.
As stated above, the GCV devices released ganci
clovir at a rate of 2:0.5 tug/hr (?rst type) and 5:1

sion cell (Crown Glass Co., Somerville, NJ). The in

ug/hr (second type).

heat cured in a convection oven for 4 hours at 190° C.

ternal diameter of these cells was 1 cm (total surface
area of diffusion 0.78 01112); the volume of each compart
ment was 3 ml. Small magnetic stirring rods were

Device/Drug Stability

placed in each compartment and operated by a mag
netic stirring unit. The entire assembly was maintained

Near IR of the individual components (EVA, PVA
and ganciclovir) showed no change after heat treat
ment; however, the device showed a single new peak at

at 37° C by a circulating water bath. Membranes were

approximately 2075 nm. In addition, there was no ap

minutes and then loaded into the chambers. With the
membrane in place, buffer solution was added to each

of the ganciclovir pellet based on HPLC analysis, and a
scanning EM of the device demonstrated that there
were no holes or cracks in the walls of the device after
heat treatment.

?rst soaked in isotonic buffered saline (pH 7.4) for 30 20 parent drug loss or decomposition after heat treatment

compartment and left in place for 30 minutes to allow
for hydration of the membrane and then removed. A
0.025% solution of GCV in isotonic buffered saline was
added to the donor compartment and the buffer solution
was added to the receptor compartment. The contents
of the receptor compartment were periodically re

moved for analysis and replaced with fresh buffer solu
tion thus maintaining sink conditions.
An ultraviolet spectrophotometry assay was used to

determine concentrations of ganciclovir (252 nm, detec
tion limit 0.1 pig/cc). A linear relationship between
absorbance and concentration was demonstrated using
known concentrations of drug in a tear buffer solution.
Sheets of EVA membrane were prepared by com
pressing 3.5 gm pellets under 4 metric tons at 190° C to

25

EXAMPLE 3
Intravitreal Sustained Release of Ganciclovir: In Vivo

Pharmacokinetics and Tolerability
The membrane permeability studies, the construction
of the implants and the in vitro release rate studies of the
implants used in this study are described in Example 2.
Implants releasing 2 or 5 pg/hr in vitro were prepared.
Implants were sterilized with ethylene oxide gas by the
Sterile Products Division of the Veterans Administra

tion Hospital in Lexington, Ky. Quality control was
ensured by measuring the in vitro release rate of every
?fth device. Sterility -was ensured by sending every

PVA. It was found that GCV did not permeate through

?fth device for culture.
New Zealand albino rabbits weighing 1.5 to 2 kg
were used in this study. Anesthesia was provided with

the EVA layer.

intramuscular ketamine HCl (40 mg/kg), attopine sul

a thickness of 0.6 mm. Diffusion cell studies were per
formed with EVA membranes as described above for

fate (0.1 mg/kg), xylazine HCl (10 mg/kg) and topical

Device Construction
proparacaine (0.5%). Pupillary dilation was achieved
Because EVA was found to be impermeable to ganci 45 with topical phenylephrine (2.5%) and tropicamide
clovir it was used in these devices as a blocking agent.
EVA membranes were prepared as described above. A

(1%) drops.

A baseline photopic electroretinogram (ERG) was
recorded preoperatively in each rabbit using a corneal
six milligram pellet of GCV was compressed under 500
contact lens. A Gansfeld stimulus was used to improve
pounds of pressure into pellets measuring 2.5 mm in
diameter.
50 standardization of results. After sedation, the rabbits
A first type of sustained release GCV device releas

were placed inside a Gansfeld stimulator 20 cm away

ing 2 ug/hr was prepared by coating the 6 mg pellet of

from the ?ash unit. Flash (cone and rod response) and
?icker (cone response) ERGs were done under light

ganciclovir in 300 p1 of a 10% PVA solution and allow
ing the coated pellet to dry. The pellet was then coated
on three sides with a ?lm of prepressed EVA and
capped by a 3 mm disc of EVA coated in 10% PVA.
The pellet was thus completely surrounded by EVA
apart from a thin ring of PVA between the EVA walls
and the cap. See FIG. 2. The assembly was then com

adapted conditions. Graphic measurements were re

corded, and the waveform amplitudes and implicit
times were calculated.

Cryopexy was then applied to the superior 180 de
grees of the peripheral retina in each eye to decrease the
chance of retinal detachment related to EVA/PVA
membrane insertion or vitreous sampling. This was
done because the pars plana of the New Zealand albino
rabbit is poorly developed and it was therefore neces
sary to implant the devices and take vitreous samples
through retina. The ERG was repeated four weeks later

pletely coated in 10% PVA and allowed to dry over
night. The embedded pellet was cut out in a disc shape
using a 4 mm punch. A suturing strut was attached to
the device by bonding a strip of dry 10% PVA to the
bottom of the device with a drop of 2% PVA. The
device was subsequently baked at 190° C for 4.75 hours. 65 immediately prior to insertion of the device.
All intraocular procedures were done under sterile
A second type of device releasing 5 ug/hr was pre
conditions and conformed to the ARVO speci?cations
pared in the same manner except that GCV pellets had
for the ethical treatment of experimental animals. After
only the top and bottom surfaces covered with EVA.

15
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placement of a lid speculum, a 360 degree conjunctival

tion. The calculated mean in vivo release rate was ap

peritomy was performed. The rectus muscles were se

proximately 5 ug/hr. No detectable drug was measured
72 days after device implantation in any eye from the

cured with 2-0 black silk suture. Using indirect ophthal

?rst group. In the second group, GCV was present in
the vitreous at over 2 ug/ml for over 80 days. Im
planted devices were found to have released GCV at

moscopy, the area of previous cryopexy was localized

and marked with scleral diathermy.
The EVA/PVA device was immersed in sterile saline
prior to placement of a 7-0 silk suture through the exter
nal PVA supporting tag. A MVR blade was used to

approximately 2 ug/hr in vivo. This would suggest that

create a 5 mm sclerotomy site through the area

mately 120 days.

levels would be maintained in the vitreous for approxi

cryopexy. Penetration into the vitreous was veri?ed by
direct visualization of the MVR blade through the di

The device was well tolerated in both groups demon

strating no evidence of intraocular in?ammation by
indirect ophthalmoscopy. Five treatment eyes from the

lated pupil. The device was placed into the vitreous
cavity and secured to the sclera with the 7-0 silk suture
that was attached to the external PVA supporting tag.
Remaining defects in the sclera were closed with 7-0
silk in an interrupted fashion. Topical antibiotic drops

the second group developed lens opaci?cation (0/19,
0%). Two of the 5 eyes that developed lens opaci?ca

consisting of polymyxin B, bacitracin, and neomycin

tion developed a dim use white cataract after direct

?rst group developed lens opaci?cation (5/9, 56%).
None of the eyes from the control group or eyes from

trauma to the lens during vitreous sampling. The other
after each procedure.
eyes that developed lens opaci?cation developed a fo
In a ?rst group of nine rabbits, the right eye was 20 cal, nonprogressive lens opacity also believed to be
related to vitreous sampling. No cataract formation
treated with a device without GCV (control eyes),
while the left eye was given a device containing 6 mg of
occurred in any of the eyes in which a device containing
ganciclovir was placed and no vitreous sampling was
GCV releasing at 5:1 ug/hr (treatment eyes). Vitreous
samples were periodically removed using a 20 gauge
performed.

were instilled into each eye twice daily for three days

needle on a tuberculin syringe. Entrance into the vitre
ous cavity was veri?ed by observation of the needle

Retinal detachment occurred in two treatment eyes
(2/9, 22%) from group one and in none of the eyes from
the control group or the eyes from the second group

through the dilated pupil. Retinal examination with
indirect ophthalmoscope was performed on each eye

(O/l9, 0%). Both retinal detachments were thought to
prior to each vitreous sampling. After removal, vitreous
be related to traumatic vitreous sampling and not a
samples were stored at -60° C until analyzed by 30 secondary response to the device.

HPLC. ERG’s were repeated one and two months after

No detachments or other abnormalities occurred in
the second group of animals which were not periodi

device implantation.

cally sampled.

After the last ERG, the rabbits were sacri?ced with
an overdose of intravenous sodium pentobarbital. At

Flash (rod and cone response) and ?icker (cone re

this time, no GCV was detectable in the vitreous. Enu 35 sponse) ERG measurements were obtained preopera

tively and postoperatively in all eyes. No signi?cant

cleated eyes were ?xed in 70% formaldehyde

glutaraldehyde solution, dehydrated in alcohol, embed

deterioration of the ?ash or ?icker ERG wave ampli

ded in paraf?n, and sectioned with microtome. Tissues
were stained with hematoxylin-eosin and examined
under a light microscope.

tudes occurred in either group one or two eyes. No

signi?cant prolongation of the ERG implicit times oc
curred in either group. Modest abnormalities seen in the

postoperative ERG b-wave amplitudes and implicit

In a second group of 10 rabbits, a device containing 6

mg of GCV releasing at 2i0.5 ug/hr was implanted

times were most likely related to the cryopexy.

into both eyes. Vitreous samples were not collected
from the treated eyes. Instead, the rabbits were sacri

Histological examination of the retina showed no
signi?cant difference between the control and treatment
?ced 10, 30, 40, 70 and 80 days after implantation. As 45 eyes. Light microscopic examination of both groups
with the ?rst group, retinal examination was performed
revealed normal retinal architecture.
with an indirect ophthalmoscope and ERGs were per

The two eyes from the ?nal group that received a 6
mg bolus dose of intravitreal GCV showed no evidence

formed immediately prior to sacri?ce. In this group,
devices were removed from the eyes and the amount of

GCV still present determined by HPLC.
The animals were killed with an overdose of intrave
nous sodium pentobarbital when no detectable GCV
was present in the treatment eyes. Enucleated eyes were

50

of toxicity by indirect ophthalmoscopy. Postopera
tively, the photopic ?ash ERG remained unchanged
throughout, while the photopic ?icker ERG showed a
50% deterioration in b-wave amplitude and modest

delay in implicit time beginning 48 hours after GCV

?xed in 20% formaldehyde-glutaraldehyde solution,

administration. The ?icker ERG completely recovered
dehydrated in alcohol, embedded in paraf?n, and sec 55 in one eye and partially in the other 48 days after GCV
tioned with a microtome. Tissues were stained with
administration.
hematoxylin-eosin and examined by light microscopy.
No observable retinal toxicity was present by ERG
In the ?nal experimentation group, 6 mg of GCV was
or light microscopic examination of retinal tissue post
placed into the vitreous of one rabbit (both eyes)
operatively. Chronic low concentrations of GCV ap
through the pars plana to assess retinal toxicity in the 60 pear to be well tolerated by the retina. Although some
“worst case scenario” event of immediate device break
ERG changes were noted with the implantation of 6 mg
down. ERGs were done preoperatively and on postop
of uncoated GCV it does not appear that complete
erative days 2, l1, and 48.
device breakdown would result in permanent retinal
damage. We believe that the cataracts which formed in
Results

65 the 5 eyes of group one were secondary to lens trauma

In this investigation, mean GCV vitreous concentra
tions in the ?rst group ranged from 14 ug/ml to 19

from the repeated vitreous taps rather than drug toxic
ity. No lens opaci?cation occurred in either the eyes

pg/ml for 42 to 56 days after EVA/PVA device inser

from the control group or the eyes from the second

5,378,475
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group in which frequent vitreous taps were not per
formed.
The device was easily inserted through the area of
cryopexy in the rabbit. Applicants believe that the reti

18
TABLE 3
Progression of CMV in Patients

Treated with Implant

nal detachments seen in two treatment eyes of the ?rst

group were a re?ection of the dif?culty working with

PATIENT

TREATED EYE

CONTROL EYE

SFR

stable

progressed

ELM

rabbit eyes (poorly formed pars plana, low scleral rigid
ity, and large lens) rather than complications due to the

KRS

RM
BR
CMP

drug or device itself. No detachments occurred in the
eyes from the control group or the eyes from the second

group that were not undergoing frequent vitreous taps.
There was minimal in?ammatory response to the

EVA/PVA device alone. These polymers are biologi

"

improved

progressed

progressed

progressed

improved
improved
stable

no disease
no disease
progressed

CRW

improved

no d'sease

EL

improved

progressed

Visual activity was determined by a standard eye

cally inert and are well tolerated by the eye. This is a
non-biodegradable system. Although this may be con

exam and disease progression by fundus photograph.

sidered a drawback, the reliable release rates over ex

by high performance liquid chromatography (HPLC)

Samples of vitreous from human eyes were analyzed

tended periods of time and the lack of in?ammatory
response would be very dif?cult to obtain using an

using a C-l8 reverse phase column with a 0.02% ammo

nium acetate mobile phase (pH 4.0). Under these condi

erodible drug delivery system. Our in vitro release rates
tions, GCV has a retention time of 31 minutes. This
seem to be predictive of the in vivo release rate. In the 20 work has shown that implantation of the devices main
eyes from the second group, drug devices were con
tains GCV levels of approximately 1.5 ug/ml in the
structed to release GCV at a slower rate to extend the
vitreous for over 70 days.

duration of treatment. Increasing the amount of drug
carried in the device would also be technically simple 25
and could extend the duration of GCV release to the
vitreous for several months.

Membrane System of Layered Ethylene Vinyl Acetate
and Polyvinyl Alcohol
In Vitro Studies
subconjunctival administration of 5-FU as an adjunct
to ?ltration surgery in high risk glaucoma patients is

EXAMPLE 4

Intravitreal Sustained Release of Ganciclovir In Vivo

Pharmacokinetics and Tolerability: Human Studies
The membrane permeability studies, the construction
of the implants and the in vitro release rates studies of

the implants used in this study are described in Example
2. The devices used were those which released GCV at 35

2 pg/hr.
Eight humans infected with AIDS were used in this
study. One eye of each patient treated with an implant

containing ganciclovir. The implant was surgically po

EXAMPLE 5

Sustained Release of S-FU Using a Heat Treated

attended by the necessity of multiple subconjunctival
injections and the potentially serious complications due
to delayed wound healing. Alternative delivery systems

have been proposed including liposomes, topical admin
istration, and sustained release polymers. Work with
diffusion of S-FU through ethylene vinyl acetate (EVA)
and polyvinyl alcohol (PVA) membranes showed that

sitioned within the vitreous. The other eye of each 40 EVA was impermeable to S-FU while PVA provided a
linear release that appeared to be optimal for the sus
patient was used as a control, that is, was not treated

tained release of 5-FU (J. Ocular Pharmacol.
with ganciclovir. In all eight patients, vision stabilized
1988;10622231). Applicants found that release rates
in the eye treated with the implant. See Table 2 below.
could be markedly decreased by heat treating the PVA
In Table 2, the ?rst column indicates the initials of the
patient. The second column indicates the visual acuity 45 membrane. Nonetheless, Applicants found that an im
proved system could be made by optimizing the release
of the patient prior to implantation. The third column
rate using a layered EVA/PVA system. Therefore, the
indicates the visual acuity of the patient on the last day,
the vision of the patient was checked before death.
TABLE 2
Vision of Patients Treated With

Implant
PATIENT
SFR
ELM

BEFORE

AFTER

DAYS

20/70
20/20

20/70
20/25

21
28

KRSl

ci=2

cF2

24

RM
BR
CMP
CRW
EL

20/80
20/20
20/30
20/40
20/20

zo/so
20/40
20/30
20/40
20/40

19
26
9
7
50

rate of release was further decreased by layering EVA

_within the PVA to create a membrane system that was
6X8 mm in size.

Device Construction
A 6 milligram pellet of S-FU was compressed under
500 pounds of pressure into pellets measuring 2.5 mm in
55 diameter. Sustained release S-FU devices were pre

pared by'coating the 6 mg pellet of 5-FU in 300 pl of a
10% PVA solution and allowed to dry. The pellet was
then coated on three sides with a ?lm of prepressed
EVA and capped by a 3 mm disc of EVA coated in

10% PVA. The pellet was thus completely surrounded
by EVA apart from a thin ring of PVA between the
EVA walls and the cap. See FIG. 2. The assembly was
2Count Fingers Vision Failure
then completely coated in 10% PVA and allowed to
dry overnight. The embedded pellet was cut out in a
In addition, progression of the disease arrested or
reversed in the eye treated with ganciclovir. Table 3 65 disc shape using a 3.5 mm punch. A suturing strut was
attached to the device by bonding a strip of dry 10%
below and the photography in FIG. 5 show the progres~
PVA to the bottom of the device with a drop of 2%
sion of the disease. FIG. 4 shows the concentration of
PVA. The device was subsequently baked at 190° C for
GCV over time.
lRetina was detached at time of implantation but was repaired during implantation.
Subsequently, the retina redetached.

19
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the spirit and scope thereof, can make various changes
and/or modifications of the invention to adapt it to
various usages and conditions. As such, these changes
and/or modi?cations are properly, equitably and in
tended to be, within the full range of equivalence of the

three hours. With this design, Applicants were able to
decrease the release rate to approximately 4 pg/hr
(4.16:0.43 ug/hr, n= 3) and to sustain the release over
one month in vitro.

In Vivo Studies
The above-described devices were implanted subcon
junctivally in four rabbits to study possible in vivo tox

following claims.
We claim:

,

1. A method for treating a mammalian organism to
obtain a desired local or systemic physiological or phar

icity from the device and S-FU.

Devices containing 6 mg of S-FU were implanted on 10 macological effect comprising:
the exposed sclera 1.0 mm from the limbus superiorly in
administering a sustained release drug delivery sys
the right eye of four rabbits under general anesthesia.
tem to a mammalian organism in need of such treat

The left eye was undisturbed and used as a control.

ERG’s and funclus photographs done prior to sacri
?cing showed no retinal toxicity from the device or the 15
5-FU. Intraocular pressure measurements showed no

systemic physiological or pharmacological effect,
(2) a ?rst polymer coating layer, said ?rst coating
layer essentially impermeable to the passage of said
agent, and said ?rst polymer coating layer covering

signi?cant difference between the eyes. Histology on
the implanted eye showed no in?ammation related to

the device or other histologic abnormality. Devices
retrieved after sacri?cing were found to have no drug
remaining in them. We have shown that our system for

at least a portion of the inner core, wherein at least
a small portion of the inner core is not coated with

sustained release is biologically inert and releases S-FU

said ?rst coating layer, and
(3) ‘a second polymer coating layer permeable to the

at a rate that does not achieve toxic level. We feel this

method of delivery has great promise in the therapy of
the glaucoma patient at risk for failure of ?ltration sur 25
gery.

EXAMPLE 6
Sustained Release of 5-FU Using a Heat Treated

Membrane System of Layered Ethylene Vinylacetate
and Polyvinyl Alcohol

ment, said drug delivery system comprising;
(1) an inner core or reservoir comprising an effective
amount of an agent to obtain a desired local or

passage of said agent, wherein said second polymer

coating layer essentially completely covers said
?rst polymer coating layer and the uncoated por
tion of the inner core, whereby said agent is able to

pass through said second polymer coating layer in
30

Device Construction

A twelve milligram pellet of S-FU was compressed
under 500 pounds of pressure into pellets measuring 2.5

a controlled manner wherein said ?rst polymer

coating layer and said second polymer coating
layer are essentially insoluble and inert in body
?uids.
2. A method for treating a mammalian organism as

claimed in claim 1, wherein said second coating layer
mm in diameter. Sustained release S-FU devices were 35 comprises polyvinyl alcohol.
prepared by coating the 12 mg pellet as described in
3. A method for treating a mammalian organism as
Example 5.
claimed in claim 2, wherein said ?rst coating layer com
prises ethylene vinyl acetate.
Release Rate Studies

4. A method for treating a mammalian organism as
The devices were placed in 10 ml of isotonic buffered 40 claimed in claim 3, wherein said effective agent com
saline at 37° C. The solution was periodically sampled
prises 5-?uorouracil or ganciclovir.
and changed to maintain sink conditions. The concen
5. A method for treating a mammalian organism for
tration of GCV in these samples was determined by
HPLC with UV detection at 254 nm absorbance. Ab

sorbance values of the samples were converted to drug 45

concentrations and cumulative drug release (average of
three trials) was plotted against time. See FIG. 5.
In Vivo Studies
Implants prepared as described above were surgically 50

implanted in the eyes of monkeys which have under
gone ?ltering surgery. Intraocular pressure (IOP) tends
to increase in monkeys which have undergone ?ltering
surgery. Thus, the aim of this study was to maintain low
IOP in monkeys after ?ltering surgery by the use of a 55
sustained release 5-FU. In one eye of each monkey, a

device containing 12 mg of S-FU was implanted under
the conjunctiva after surgery. In the other eye of each
monkey, a device containing no 5-FU was implanted
under the conjunctiva after surgery.
FIG. 6 illustrates the intraocular pressure of a mean
average of three monkeys versus time in days. As
clearly illustrated, the treated eyes maintained an intra
ocular pressure below that of the untreated (control)

cytomegalovirus retinitis comprising:

administering a sustained release drug delivery sys
tem to a mammalian organism in need of such treat

ment, said drug delivery system comprising;
(1) an inner core or reservoir comprising an effective
amount of ganciclovir effective to obtain a desired

local or systemic physiological or pharmacological

effect,
(2) a ?rst polymer coating layer, said ?rst polymer
coating layer essentially impermeable to the pas
sage of said ganciclovir, and said ?rst polymer
coating layer covering at least a portion of the
inner core, wherein at least a small portion of the
inner core is not coated with said ?rst polymer

coating layer, and
(3) a second polymer coating layer permeable to the
passage of said ganciclovir, wherein said second

polymer coating layer essentially completely cov

ers said ?rst polymer coating layer and the un
coated portion of the inner core, whereby said
ganciclovir is able to pass through said second
polymer coating layer in a controlled manner.
65
eyes.
6. A method for treating a mammalian organism to
From the foregoing description, one of ordinary skill
obtain a desired physiological or pharmacological effect
in the art can easily ascertain the essential characteris
comprising:
tics of the instant invention, and without departing from

21
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placing a sustained release drug delivery system in

22

wherein said inner coating of said inner core comprises

contact with or within an eye of a mammalian

polyvinyl alcohol.

organism in need of such treatment, said drug de

14. The sustained release drug delivery system suit
able for placing in the eye according to claim 12,

livery system comprising;
(I) an inner core having an effective amount of an

wherein said ?rst coating comprises ethylene vinyl

agent to obtain a desired local or systemic physio

acetate.

logical or pharmacological effect and an inner pol
ymer coating permeable to the passage of said
agent covering at least a portion of said agent,
(2) a ?rst polymer coating essentially impermeable to
the passage of said agent, said ?rst polymer coating
covering at least a portion but not the entire surface
area of said inner polymer coating of said inner

15. The sustained release drug delivery system suit
able for placing in the eye according to claim 12,
wherein said second coating comprises polyvinyl alco
hol.
16. A method for providing controlled and sustained
administration of an agent effective in obtaining a de

core, and

(3) a second polymer coating permeable to the pas 15
sage of said agent, wherein said second polymer

coating essentially completely covers said ?rst
polymer coating and any uncoated portion of the
20

wherein each of the polymers selected to make the
device are essentially insoluble and inert in body

?uids and compatible with eye tissues, and

(1) an inner core or reservoir comprising an effective
amount of an agent effective in‘obtaining a desired

physiological or pharmacological effect,
(2) a polymer coating layer which is essentially im
permeable to the passage of said effective pgent,

said impermeable layer covering at least a portion

allowing said agent to pass through said second poly
mer coating to obtain a desired effect.

ery system at a desired location, said drug delivery

system comprising;

inner core, whereby said agent is able to pass

through said second polymer coating,

sired local or systemic physiological or pharmacologi
cal‘ effect comprising:
surgically implanting a sustained release drug deliv

25

7. The method for treating a mammalian organism
according to claim 6, wherein said inner coating of said
inner core comprises polyvinyl alcohol.

8. The method for treating a mammalian organism
according to claim 6, wherein said ?rst coating com 30

prises ethylene vinyl acetate.
9. The method for treating a mammalian organism
according to claim 6, wherein said second coating com

or the inner core, wherein at least a small portion of
the inner core is not coated with said impermeable

polymer coating layer, and
(3) a polymer coating layer which essentially com
pletely covers the inner core and is permeable to

the passage of said effective agent whereby said
agent is able to pass through said polymer coating
layer in a controlled manner.
17. A method as claimed in claim 16, wherein said

prises polyvinyl alcohol.

device is surgically implanted within the vitreous of the
10. The method for treating a mammalian organism 35 eye.
according to claim 6, wherein said agent is ganciclovir
18. The sustained release drug delivery system suit
or 5~?uorouracil.
able for placing in the eye according to claim 12,
11. The method for treating a mammalian organism
wherein said agent is cyclosporin, dexamethasone, 5
according to claim 6, wherein said inner coating of said
?uorouracil or ganciclovir.
inner core comprises polyvinyl alcohol, said ?rst coat 40 19. A method as claimed in claim 17, wherein said

ing comprises ethylene vinyl acetate, said second coat
ing comprises polyvinyl alcohol and said agent is cy

permeable coating layer comprises polyvinyl alcohol.

closporin, dexamethasone, 5-?uorouracil or ganci

impermeable coating layer comprises ethylene vinyl

clovir.

20. A method as claimed in claim 18, wherein said
acetate.

12. A sustained release drug delivery system suitable 45
21. A method as claimed in claim 20, wherein said
for placing in contact with or within the eye to provide
effective agent is ganciclovir or 5-?uorouracil.

a desired physiological or pharmacological effect com

prising:
(1) an inner core having an effective amount of an

agent to obtain a desired local or systemic physio

logical or pharmacological effect and an inner pol
ymer coating permeable to the passage of said
agent covering at least a portion of said agent,
(2) a ?rst polymer coating essentially impermeable to
the passage of said agent, said ?rst polymer coating 55
covering at least a portion but not the entire surface

area of said inner polymer coating of said inner
core, and

(3) a second polymer coating permeable to the pas
sage of said agent, wherein said second polymer 60
coating essentially completely covers said ?rst
polymer coating and any uncoated portion of the
inner core,

wherein each. of the polymers selected to make the
device are essentially insoluble and inert in body 65
?uids and compatible with eye tissues.
13. The sustained release drug delivery system suit
able for placing in the eye according to claim 12,

22. A sustained release drug delivery system compris
mg:
(A) an inner core or reservoir comprising an effective
amount of an agent effective in obtaining a desired

local or systemic physiological or pharmacological

effect,
(B) a ?rst polymer coating layer, said ?rst polymer
coating layer impermeable to the passage of said
effective agent, and said ?rst polymer coating layer
covering at least a portion of the inner core,
wherein at least a small portion of the inner core is

not coated with said ?rst polymer coating layer,
and

(C) a second polymer coating layer, said second poly
mer coating layer permeable to the passage of said
effective agent, wherein said second polymer coat
ing layer essentially completely covers the ?rst

polymer coating layer and the uncovered portion
of the inner core, said ?rst polymer coating layer
and said second polymer coating layer being essen
tially insoluble and inert in body ?uids.

23
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(c) a second polymer coating layer, said second poly

23. A sustained release drug delivery system as
claimed in claim 22, wherein said second coating layer

comprises polyvinyl alcohol.

mer coating layer permeable to the passage of said
effective agent, wherein said second polymer coat

24. A sustained release drug delivery system as
claimed in claim 23, wherein said ?rst coating layer

ing layer essentially completely covers the ?rst
polymer coating layer and the uncovered portion

comprises ethylene vinyl acetate.

of the inner core, wherein said sustained drug de

25. A sustained release drug delivery system as
claimed in claim 24, wherein said effective agent is
ganciclovir or 5-fluorouracil.
26. The method for treating a mammalian organism as

livery system is attached to an intraocular lens or

the haptic extending from said intraocular lens.
30. The sustained drug release delivery system as
claimed in claim 29, wherein said effective agent is
ganciclovir, 5-?uorouracil, colchicine or dexametha

claimed in claim 1, wherein said drug delivery system is

attached to an intraocular lens or the haptic extending
sone.
from said intraocular lens.
31. The method for treating a mammalian organism
27. The sustained release drug delivery system suit
according to claim 1, wherein said sustained release
able for placing in the eye according to claim 12, 15 drug delivery system is placed in contact with or within
wherein said inner coating of said inner core comprises
an eye of said mammalian organism.
32. The method for treating a mammalian organism
polyvinyl alcohol, said ?rst coating comprises ethylene
according to claim 1, wherein said sustained release
vinyl acetate, said second coating comprises polyvinyl
alcohol and said agent is ganciclovir or 5-?uorouracil.
drug delivery system further comprises a polymeric
28. The sustained release drug delivery system ac
layer between said inner core or reservoir and said

cording to claim 22, further comprising a polymeric

impermeable coating, whereby said agent is able to pass

layer between said inner core or reservoir and said

through said polymeric layer between said inner core or

impermeable coating, whereby said agent is able to pass

reservoir and said impermeable coating.

through said polymeric layer
29. A sustained release drug delivery system compris

33. The method for treating a mammalian organism
25 according to claim 22, wherein said core consists essen

tially of said agent or a pharmaceutically acceptable salt
of said agent.
34. The method for treating a mammalian organism

mg:
(a) in inner core or reservoir comprising an effective
amount of an agent effective in obtaining a desired

local or systemic physiological or pharmacological

effect,

according to claim 1, wherein said core consists essen
30

(b) a ?rst polymer coating layer, said ?rst polymer
coating layer impermeable to the passage of said
effective agent, and said ?rst polymer coating layer
covering at least a portion of the inner core,

tially of said agent or a pharmaceutically acceptable salt
of said agent.
35. The sustained release drug delivery system ac
cording to claim 22, wherein said polymers used to
fabricate said ?rst and second layer are compatible with

wherein at least a small portion of the inner core is 35 eye tissues. between said inner core or reservoir and

said impermeable coating.

not coated with said ?rst polymer coating layer,
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